HPS Pharmacies wish to advise that Pfizer is anticipating a supply interruption for Bicillin® L-A as follows:
Bicillin L-A
Benzathine benzylpenicillin tetrahydrate 1,200,000 Units / 2.3 mL
ARTG 147169
This supply interruption is expected to occur between 20 December 2024 and 10 January 2025.
The Therapeutic Goods Administration (TGA) has authorised the supply of an internationally registered alternative under Section 19A of the Therapeutic Goods Act 1989. This product is also listed on the Pharmaceutical Benefits Scheme (PBS).
The S19A alternative requires reconstitution prior to administration and its final volume is approximately double that of the Australian version. This should be considered when deciding on the clinical appropriateness of this alternative. Reconstitution may be undertaken with 0.5% injectable lidocaine solution (not supplied) to reduce pain at the injection site.
Other key differences between the products are shown in the table below.
| Bicillin® L-A | Extencilline® (S19A alternative) |
|
| Expression of active ingredient | Benzathine benzylpenicillin tetrahydrate |
Benzathine benzylpenicillin |
| Appearance | White fluid suspension Pre-filled syringe |
Vial of powder + ampoule of solvent for suspension |
| Volume required for 1.2 million IU dose | 2.3 mL | 4 mL diluent + powder = 5 mL (approx.) |
| Preparation | Pre-filled single use syringe | Reconstitute immediately before use |
| Labelling | English | French |
| Storage conditions | 2-8°C (storage at 30°C allowed for single period of 2 months) |
Below 25°C |
For further information, including important safety considerations, please refer to the fact sheet produced by the Australian Commission on Safety and Quality in Health Care.
Please note: the lower strength of Bicillin L-A (600,000 Units/1.7mL) continues to experience a long-term supply interruption. Normal supplies of this product are not expected to return until end-April 2025.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pfizer on 1800 675 229, or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates